171 related articles for article (PubMed ID: 36322860)
1. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cliff ERS; Mian H; Mohyuddin GR
N Engl J Med; 2022 Nov; 387(18):1721-1722. PubMed ID: 36322860
[No Abstract] [Full Text] [Related]
2. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Hindié E
N Engl J Med; 2022 Nov; 387(18):1721. PubMed ID: 36322859
[No Abstract] [Full Text] [Related]
3. Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.
Moreau P; Girgis S; Goldberg JD
N Engl J Med; 2022 Nov; 387(18):1722-1723. PubMed ID: 36322861
[No Abstract] [Full Text] [Related]
4. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
6. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
Firestone R; Lesokhin AM; Usmani SZ
Blood Cancer Discov; 2023 Nov; 4(6):433-436. PubMed ID: 37824758
[TBL] [Abstract][Full Text] [Related]
7. [Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy].
Le Grand S; Karlin L
Bull Cancer; 2023 Sep; 110(9):871-872. PubMed ID: 37296008
[No Abstract] [Full Text] [Related]
8. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
9. Teclistamab: First Approval.
Kang C
Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
[TBL] [Abstract][Full Text] [Related]
10. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Moore DC; Granger K; Hill H; Karabinos A; Davis JA
Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
[No Abstract] [Full Text] [Related]
11. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract][Full Text] [Related]
12. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
13. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
14. [Teclistamab for the treatment of multiple myeloma].
Sester LS; Goldschmidt H; Nitschmann S
Inn Med (Heidelb); 2023 Feb; 64(2):214-216. PubMed ID: 36478107
[No Abstract] [Full Text] [Related]
15. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
16. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
17. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Krishnan A; Nooka AK; Chari A; Garfall AL; Martin TG; Nair S; Lin X; Qi K; Londhe A; Pei L; Ammann E; Kobos R; Smit J; Parekh T; Marshall A; Slavcev M; Usmani SZ
J Comp Eff Res; 2023 Jun; 12(6):e220186. PubMed ID: 37114426
[No Abstract] [Full Text] [Related]
18. [New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment].
Try M; Karlin L
Bull Cancer; 2021 Jun; 108(6):563-565. PubMed ID: 34020786
[No Abstract] [Full Text] [Related]
19. Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma.
Hammons LR; Szabo A; Janardan A; Dhakal B; Chhabra S; D'Souza A; Mohan M
JAMA Netw Open; 2022 Oct; 5(10):e2238961. PubMed ID: 36306135
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].
Bi JY; Wen L; Duan WB; Liu Y; Wang SS; Huang XJ; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):146-149. PubMed ID: 35381676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
